LUVANTAS Trademark

Trademark Overview


On Tuesday, December 13, 2022, a trademark application was filed for LUVANTAS with the United States Patent and Trademark Office. The USPTO has given the LUVANTAS trademark a serial number of 97715850. The federal status of this trademark filing is REGISTERED as of Tuesday, August 20, 2024. This trademark is owned by Medytox Inc.. The LUVANTAS trademark is filed in the Pharmaceutical Products category with the following description:

Implantable medicines for treating neurological disorders and muscle dystonia; implantable antiaging medicines, namely, botulinum toxin for medical use for treatment of facial wrinkles; pharmaceuticals containing botulinum toxin for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, excessive eye blinking, neuropathy pain and pelvic pain; pharmaceutical syringes prefilled with medical botulinum toxin as the main ingredient for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, excessive eye blinking, neuropathy pain and pelvic pain
luvantas

General Information


Serial Number97715850
Word MarkLUVANTAS
Filing DateTuesday, December 13, 2022
Status700 - REGISTERED
Status DateTuesday, August 20, 2024
Registration Number7477829
Registration DateTuesday, August 20, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 4, 2024

Trademark Statements


Goods and ServicesImplantable medicines for treating neurological disorders and muscle dystonia; implantable antiaging medicines, namely, botulinum toxin for medical use for treatment of facial wrinkles; pharmaceuticals containing botulinum toxin for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, excessive eye blinking, neuropathy pain and pelvic pain; pharmaceutical syringes prefilled with medical botulinum toxin as the main ingredient for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, excessive eye blinking, neuropathy pain and pelvic pain
Translation of Words in MarkThe wording "LUVANTAS" has no meaning in a foreign language

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, December 16, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMedytox Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressChungcheongbuk-do 28126
KR

Party NameMedytox Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressChungcheongbuk-do 28126
KR

Party NameMedytox Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressChungcheongbuk-do 28126
KR

Trademark Events


Event DateEvent Description
Wednesday, December 28, 2022ASSIGNED TO EXAMINER
Friday, December 16, 2022NEW APPLICATION ENTERED
Friday, December 16, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, January 5, 2023NON-FINAL ACTION E-MAILED
Thursday, January 5, 2023NON-FINAL ACTION WRITTEN
Thursday, January 5, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, March 21, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, March 21, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 21, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 26, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 30, 2023PUBLISHED FOR OPPOSITION
Wednesday, May 10, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 30, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 25, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, January 19, 2024SOU TEAS EXTENSION RECEIVED
Friday, January 19, 2024SOU EXTENSION 1 FILED
Friday, January 19, 2024SOU EXTENSION 1 GRANTED
Tuesday, January 23, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 29, 2024TEAS PETITION TO AMEND BASIS RECEIVED
Thursday, May 2, 2024NOTICE OF ALLOWANCE CANCELLED
Thursday, May 2, 2024CASE RETURNED TO EXAMINATION
Tuesday, April 23, 2024ASSIGNED TO PETITION STAFF
Thursday, April 25, 2024PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Thursday, April 25, 2024JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, May 15, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, May 29, 2024ATTORNEY REVIEW COMPLETED
Wednesday, May 29, 2024ATTORNEY REVIEW COMPLETED
Tuesday, June 4, 2024PUBLISHED FOR OPPOSITION
Tuesday, June 4, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 20, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, August 20, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED